Aβ42 peptide aggregation and deposition is an important component of the neuropathology of Alzheimer's disease (AD). Gene-gun mediated gene vaccination targeting Aβ42 is a potential method to prevent and treat AD. APPswe/PS1ΔE9 transgenic (Tg) mice were immunized with an Aβ42 gene construct delivered by the gene gun. The vaccinated mice developed Th2 antibodies (IgG1) against Aβ42. The Aβ42 levels in brain were decreased by 41% and increased in plasma 43% in the vaccinated compared with control mice as assessed by ELISA analysis. Aβ42 plaque deposits in cerebral cortex and hippocampus were reduced by 51% and 52%, respectively, as shown by quantitative immunolabeling. Glial cell activation was also significantly attenuated in vaccinated compared with control mice. One rhesus monkey was vaccinated and developed anti-Aβ42 antibody. These new findings advance significantly our knowledge that gene-gun mediated Aβ42 gene immunization effectively induces a Th2 immune response and reduces the Aβ42 levels in brain in APPswe/PS1ΔE9 mice. Aβ42 gene vaccination may be safe and efficient immunotherapy for AD.
- AD Alzheimer's disease
- APPswe/PS1deltaE9- Amyloid precursor protein(Swedish mutation)/presenilin 1 deltaE9 mutation
- Abeta- Amyloid beta
- ELISPOT- Enzyme-linked immunosorbent spot
- SPSS-Statistical Package for the Social Sciences
ASJC Scopus subject areas
- Clinical Neurology